Notable Analyst Upgrades and Downgrades (NYSE:MDR) (TSX:CUM)

Published:

A Canadian gold project developer and a U.S. bank holding company both received analyst upgrades, one of which has an implied upside of nearly 50%.

The following stocks were upgraded/downgraded on January 05, 2015
Company Name Exchange Ticker Last Price Market Cap Recommendation Analyst Name Rating Company Target Price Upside/
Downside (%)
Copper Mountain Mining Corp TSX CUM 1.59 188.9 Upgrade to buy from hold Jackie Przybylowski Desjardins Securities 3.00 88.7%
Artis Real Estate Investment Trust TSX AX-U 14.50 1,955.6 Upgrade to outperform from market perform Ken Avalos Raymond James 16.00 10.3%
Methanex Corp TSX MX 52.29 4,888.8 Upgrade to sector outperform from sector perform Ben Isaacson Scotia Capital 70.71 35.2%
H2O Innovation Inc TSXV HEO 1.45 30.3 Initiate with buy Gerard Sweeney Roth Capital Partners 2.00 37.9%
Adriana Resources Inc TSXV ADI 0.11 17.3 Downgrade to hold from buy Jackie Przybylowski Desjardins Securities 0.20 81.8%

Desjardins Securities upgraded Copper Mountain Mining Corp (TSX: CUM), engaged in the exploration and development of mineral properties, to buy from hold by raising its price target to C$3.00 from C$2.80, indicating an upside potential of 88.7% from current levels.

Artis Real Estate Investment Trust (TSX: AX-U), engaged in the business of acquiring and maintaining a portfolio of properties, with initial focus on retail and industrial commercial properties located in Western Canada, was upgraded by Raymond James to outperform from market perform with a price target of C$16.00, indicating an upside of 10.3% from current levels.

Scotia Capital upgraded Methanex Corp (TSX: MX), engaged in producing and marketing methanol, to sector outperform from sector perform with a price target of C$70.71, indicating an upside of 35.2% from current levels.

Coverage on H2O Innovation Inc (TSXV: HEO), engaged in developing systems and the technology necessary to produce high quality drinking water in Canadian and international communities, was initiated with a buy rating at Roth Capital Partners, assigning a 12-month price target of C$2.00, indicating an upside potential of 37.9% from current levels.

Desjardins Securities downgraded Adriana Resources Inc (TSXV: ADI), engaged in the exploration and production of minerals, to hold from buy with a price target of C$0.20, indicating an upside of 81.8% from current levels.

The following stocks were upgraded/downgraded on January 05, 2015
Company Name Exchange Ticker Last Price Market Cap Recommendation Analyst Name Rating Company Target Price Upside/
Downside (%)
McDermott International Inc NYSE MDR 2.95 701.06 Upgrade to overweight from equalweight Martin W Malloy Johnson Rice & Co 7.00 137.3%
Mueller Water Products Inc NYSE MWA 10.05 1,611.74 Upgrade to outperform from market perform Noah Kaye Northland Securities Inc 12.00 19.4%
Thoratec Corp NASDAQ THOR 33.08 1,819.40 Upgrade to outperform from market perform Suraj Kalia Northland Securities Inc 42.00 27.0%
NPS Pharmaceuticals Inc NASDAQ NPSP 38.13 4,073.80 Initiate with overweight Dr Geoffrey Meacham Barclays 50.00 31.1%
Actuant Corp NYSE ATU 26.27 1,662.38 Downgrade to underweight from neutral Ann Duignan JPMorgan 23.00 -12.4%

Johnson Rice & Co upgraded McDermott International Inc (NYSE: MDR), engaged in the business of providing energy services to a variety of customers in the energy and power industries, including the U.S. Department of Energy, to overweight from equal weight with a price target of $7.00, indicating an upside of 137.3% from current levels.

Mueller Water Products Inc (NYSE: MWA), engaged in manufacturing and marketing of products and services that are used in the transmission, distribution and measurement of water, was upgraded by Northland Securities Inc to outperform from market perform by raising its price target to $12.00 from $11.00, indicating an upside of 19.4% from current levels.

Northland Securities Inc upgraded Thoratec Corp (NASDAQ: THOR), engaged in researching, developing, manufacturing and marketing medical devices for circulatory support and vascular graft applications, to outperform from market perform by raising its price target to $42.00 from $26.00, indicating an upside of 27.0% from current levels.

Barclays initiated coverage on NPS Pharmaceuticals Inc (NASDAQ: NPSP), engaged in developing treatment options for patients with rare gastrointestinal and endocrine disorders and serious unmet medical needs, with an overweight rating assigning a 12-month price target of $50.00, indicating an upside of 31.1% from current levels.

Actuant Corp (NYSE: ATU), engaged in designing, manufacturing and distributing a range of industrial products and systems to various end markets, was downgraded by JPMorgan to underweight from neutral by reducing its price target to $23.00 from $28.00, indicating a downside of 12.4% from current levels.

Related articles

Recent articles